%0 Journal Article
%A Heneka, Michael
%A Carson, Monica J
%A El Khoury, Joseph
%A Landreth, Gary E
%A Brosseron, Frederic
%A Feinstein, Douglas L
%A Jacobs, Andreas H
%A Wyss-Coray, Tony
%A Vitorica, Javier
%A Ransohoff, Richard M
%A Herrup, Karl
%A Frautschy, Sally A
%A Finsen, Bente
%A Brown, Guy C
%A Verkhratsky, Alexei
%A Yamanaka, Koji
%A Koistinaho, Jari
%A Latz, Eicke
%A Halle, Annett
%A Petzold, Gabor C
%A Town, Terrence
%A Morgan, Dave
%A Shinohara, Mari L
%A Perry, V Hugh
%A Holmes, Clive
%A Bazan, Nicolas G
%A Brooks, David J
%A Hunot, Stéphane
%A Joseph, Bertrand
%A Deigendesch, Nikolaus
%A Garaschuk, Olga
%A Boddeke, Erik
%A Dinarello, Charles A
%A Breitner, John C
%A Cole, Greg M
%A Golenbock, Douglas T
%A Kummer, Markus P
%T Neuroinflammation in Alzheimer's disease.
%J The lancet  / Neurology
%V 14
%N 4
%@ 1474-4422
%C London
%I Lancet Publ. Group
%M DZNE-2020-04173
%P 388-405
%D 2015
%X Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and trigger an innate immune response characterised by release of inflammatory mediators, which contribute to disease progression and severity. Genome-wide analysis suggests that several genes that increase the risk for sporadic Alzheimer's disease encode factors that regulate glial clearance of misfolded proteins and the inflammatory reaction. External factors, including systemic inflammation and obesity, are likely to interfere with immunological processes of the brain and further promote disease progression. Modulation of risk factors and targeting of these immune mechanisms could lead to future therapeutic or preventive strategies for Alzheimer's disease.
%K Alzheimer Disease: genetics
%K Alzheimer Disease: immunology
%K Alzheimer Disease: metabolism
%K Alzheimer Disease: pathology
%K Alzheimer Disease: prevention & control
%K Animals
%K Anti-Inflammatory Agents, Non-Steroidal: therapeutic use
%K Astrocytes: immunology
%K Astrocytes: pathology
%K Biomarkers: blood
%K Biomarkers: cerebrospinal fluid
%K Brain Injuries: complications
%K Brain Injuries: metabolism
%K Clinical Trials as Topic
%K Disease Models, Animal
%K Disease Progression
%K Humans
%K Immunity, Innate
%K Immunization
%K Inflammation: diagnosis
%K Inflammation: immunology
%K Inflammation: metabolism
%K Inflammation Mediators: immunology
%K Inflammation Mediators: metabolism
%K Locus Coeruleus: pathology
%K Microglia: immunology
%K Microglia: pathology
%K Nootropic Agents: administration & dosage
%K Obesity: complications
%K Obesity: metabolism
%K Phagocytosis
%K Protein Folding
%K Risk Factors
%K Severity of Illness Index
%K Anti-Inflammatory Agents, Non-Steroidal (NLM Chemicals)
%K Biomarkers (NLM Chemicals)
%K Inflammation Mediators (NLM Chemicals)
%K Nootropic Agents (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:25792098
%2 pmc:PMC5909703
%R 10.1016/S1474-4422(15)70016-5
%U https://pub.dzne.de/record/137851